EW vs HAE
EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. HAE: Haemonetics provides essential technologies for blood and plasma collection, as well as specialized medical devices for hospital procedures and hemostasis management.
Side-by-side fundamentals
| Metric | EW | HAE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $84.24 | $119.47 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $48.6B | $5.4B | |
| P/E as of 2026-10-08 | 48.74 | 58.27 | EW lower |
| Net margin | +17.7% | +7.3% | EW higher |
| Gross margin | +78.0% | +59.0% | EW higher |
| Operating margin | +20.8% | +11.7% | EW higher |
| ROE | +10.4% | +12.2% | HAE higher |
| ROA | +7.8% | +4.1% | EW higher |
| Debt / equity as of 2026-09-03 | 0.06 | 1.40 | EW lower |
| Revenue growth (YoY) as of 2026-09-03 | +14.6% | +0.4% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +4.5% | EW higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.55 | 0.55 | |
| 1-year return as of 2026-10-08 close | +11.2% | +134.3% | HAE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.